The elusive type 2 diabetes individual achieving tight blood pressure target: A phenotypic study

Diabetes and Metabolic Syndrome: Clinical Research and Reviews

Volumn 4, Issue 4, 2010, Pages 215-219

  Hermans, Michel P ^a   Amoussou Guenou, K Daniel ^b   Ahn, Sylvie A ^a   Rousseau, Michel F ^a   Everaert, Ludwig ^c   Aerts, Ann ^d  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^b CNHU HKM   (Benin)

^c MPI bvba   (Belgium)

^d Cardiovascular and Metabolism Unit   (Belgium)

Author keywords

ESH ESC; Goal attainment; Hypertension; JNC 7; Type 2 diabetes

Indexed keywords

ACETYLSALICYLIC ACID; ALCOHOL; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ACADEMIC ACHIEVEMENT; ADULT; AGED; ALBUMINURIA; ALCOHOL CONSUMPTION; ARTICLE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; CROSS-SECTIONAL STUDY; FEMALE; GEOGRAPHIC ORIGIN; GOAL ATTAINMENT; HUMAN; HYPERTENSION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; PHENOTYPE; PRIORITY JOURNAL;

EID: 78649903141     PISSN: 18714021     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.dsx.2010.07.012     Document Type: Article

References (42)

1. International Diabetes Federation Diabetes Atlas 3rd ed. 2007 http://www.eatlas.idf.org/index.html
2. S. Perrini, A. Leonardini, L. Laviola, and F. Giorgino Biological specificity of visceral adipose tissue and therapeutic intervention Arch Physiol Biochem 114 2008 277 286
3. J.B. Meigs, M.K. Rutter, L.M. Sullivan, C.S. Fox, R.B. D'Agostino Sr., and P.W. Wilson Impact of insulin resistance on risk of type 2 diabetes and cardiovascular disease in people with metabolic syndrome Diabetes Care 30 2007 1219 1225
4. P.W. Wilson, R.B. D'Agostino, H. Parise, L. Sullivan, and J.B. Meigs Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus Circulation 112 2005 3066 3072
5. O. Pinhas-Hamiel, and P. Zeitler The global spread of type 2 diabetes mellitus in children and adolescents J Pediatr 146 2005 693 700
6. E. Grossman, F.H. Messerli, and U. Goldbourt High blood pressure and diabetes mellitus: are all antihypertensive drugs created equal? Arch Intern Med 160 2000 2447 2452
7. A.I. Adler, I.M. Stratton, H.A. Neil, J.S. Yudkin, D.R. Matthews, and C.A. Cull Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study BMJ 321 2000 412 419
8. A.V. Chobanian, G.L. Bakris, H.R. Black, W.C. Cushman, L.A. Green, and J.L. Izzo Jr. The Seventh Report of the Joint National Committee on Prevention, Detection. Evaluation, and Treatment of High Blood Pressure: the JNC 7 report JAMA 289 2003 2560 2572
9. ADVANCE Collaborative Group Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial Lancet 370 2007 829 840
10. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) JAMA 288 2002 2981 2997
11. L. Hansson, A. Zanchetti, S.G. Carruthers, B. Dahlöf, D. Elmfeldt, and S. Julius Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the hypertension optimal treatment (HOT) randomised trial Lancet 351 1998 1755 1762 (Pubitemid 28269185)
12. UK Prospective Diabetes Study Group Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38 BMJ 317 1998 703 713
13. G. Mancia, G. De Backer, A. Dominiczak, R. Cifkova, R. Fagard, and G. Germano 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) J Hypertens 25 2007 1105 1187 (Pubitemid 46924065)
14. J.C. Peterson, S. Adler, J.M. Burkart, T. Greene, L.A. Hebert, and L.G. Hunsicker Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study Ann Intern Med 123 1995 754 762
15. P.A. Sarafidis, N. Khosla, and G.L. Bakris Antihypertensive therapy in the presence of proteinuria Am J Kidney Dis 49 2007 12 26
16. V. Andros, A. Egger, and U. Dua Blood pressure goal attainment according to JNC 7 guidelines and utilization of antihypertensive drug therapy in MCO patients with type 1 or type 2 diabetes J Manage Care Pharm 12 2006 303 309
17. J. Redon, H.R. Brunner, C. Ferri, K.F. Hilgers, R. Kolloch, and G. van Montfrans Practical solutions to the challenges of uncontrolled hypertension: a white paper J Hypertens 26 Suppl. 3 2008 S1 S14
18. M.W. Stolar, B.J. Hoogwerf, S.M. Gorshow, P.J. Boyle, and D.O. Wales Managing type 2 diabetes: going beyond glycemic control J Manage Care Pharm 14 Suppl. b 2008 S2 S19
19. M. Krousel-Wood, S. Thomas, P. Muntner, and D. Morisky Medication adherence: a key factor in achieving blood pressure control and good clinical outcomes in hypertensive patients Curr Opin Cardiol 19 2004 357 362
20. C. Arauz-Pacheco, M.A. Parrott, and P. Raskin Treatment of hypertension in adults with diabetes Diabetes Care 26 Suppl. 1 2003 S80 S82
21. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: report of the expert committee on the diagnosis and classification of diabetes mellitus Diabetes Care 26 Suppl. 1 2003 S5 S20
22. D.W. Cockcroft, and M.H. Gault Prediction of creatinine clearance from serum creatinine Nephron 16 1976 31 41
23. S.M. Grundy, J.I. Cleeman, S.R. Daniels, K.A. Donato, R.H. Eckel, and B.A. Franklin Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement Circulation 112 2005 2735 2752
24. M.P. Hermans Diabetic macro- and microvascular disease in type 2 diabetes Diabetes Vasc Dis Res 4 Suppl. 2 2007 S7 S11
25. M.P. Hermans, J.C. Levy, R.J. Morris, and R.C. Turner Comparison of insulin sensitivity tests across a range of glucose tolerance from normal to diabetes Diabetologia 42 1999 678 687
26. J.C. Levy, D.R. Matthews, and M.P. Hermans Correct homeostasis model assessment (HOMA) evaluation uses the computer program Diabetes Care 21 1998 2191 2192
27. M.P. Hermans, S.A. Ahn, K.D. Amoussou-Guenou, and M.F. Rousseau Impact of metabolic syndrome on microvascular complications in type 2 diabetes Diab Metab Syndr 2010 [epub]
28. R.R. Holman, S.K. Paul, M.A. Bethel, H.A. Neil, and D.R. Matthews Long-term follow-up after tight control of blood pressure in type 2 diabetes N Engl J Med 359 2008 1565 1576
29. A.J. Owen, C. Retegan, M. Rockell, G. Jennings, and C.M. Reid Inertia or inaction? Blood pressure management and cardiovascular risk in diabetes Clin Exp Pharmacol Physiol 36 2009 643 647
30. E. Pimenta, K.K. Gaddam, and S. Oparil Mechanisms and treatment of resistant hypertension J Clin Hypertens (Greenwich) 10 2008 239 244
31. C.E. Jackson, S.D. Solomon, H.C. Gerstein, S. Zetterstrand, B. Olofsson, and E.L. Michelson Albuminuria in chronic heart failure: prevalence and prognostic importance Lancet 374 2009 543 550
32. C. Meisinger, M. Heier, R. Landgraf, M. Happich, H.E. Wichmann, and W. Piehlmeier Albuminuria, cardiovascular risk factors and disease management in subjects with type 2 diabetes: a cross sectional study BMC Health Serv Res 8 2008 226
33. G. Bruno, P. Cavallo-Perin, G. Bargero, M. Borra, V. Calvi, and N. D'Errico Prevalence and risk factors for micro- and macroalbuminuria in an Italian population-based cohort of NIDDM subjects Diabetes Care 19 1996 43 47
34. K. Matsumoto, N. Fujita, K. Nakamura, T. Senoo, T. Tominaga, and Y. Ueki Apolipoprotein B and insulin resistance are good markers of carotid atherosclerosis in patients with type 2 diabetes mellitus Diabetes Res Clin Pract 82 2008 93 97
35. G. Slama, E. Eschwge, M.H. Bernard, A. Grimaldi, J.M. Oppert, and D. Pouchain One-year follow-up in real clinical practice conditions of type 2 diabetic patients treated with rosiglitazone: the Avantage study Ann Endocrinol (Paris) 69 2008 36 46
36. E. Karagiannis, A. Pfützner, T. Forst, G. Lübben, W. Roth, and M. Grabellus The IRIS V study: pioglitazone improves systemic chronic inflammation in patients with type 2 diabetes under daily routine conditions Diabetes Technol Ther 10 2008 206 212
37. D.C. Goff Jr., H.C. Gerstein, H.N. Ginsberg, W.C. Cushman, K.L. Margolis, and R.P. Byington Prevention of cardiovascular disease in persons with type 2 diabetes mellitus: current knowledge and rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial Am J Cardiol 99 2007 4i 20i
38. E. Selvin, S. Marinopoulos, G. Berkenblit, T. Rami, F.L. Brancati, N.R. Powe, and S.H. Golden Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus Ann Intern Med 141 2004 421 431
39. H.C. Gerstein, J. Pogue, J.F. Mann, E. Lonn, G.R. Dagenais, and M. McQueen The relationship between dysglycaemia and cardiovascular and renal risk in diabetic and non-diabetic participants in the HOPE study: a prospective epidemiological analysis Diabetologia 48 2005 1749 1755
40. I.M. Stratton, A.I. Adler, H.A. Neil, D.R. Matthews, S.E. Manley, and C.A. Cull Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study BMJ 321 2000 405 412
41. P.M. Kearney, L. Blackwell, R. Collins, A. Keech, J. Simes, and R. Peto Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis Lancet 371 2008 117 125
42. J.B. Echouffo-Tcheugui, L.A. Sargeant, A.T. Prevost, K.M. Williams, R.S. Barling, and R. Butler How much might cardiovascular disease risk be reduced by intensive therapy in people with screen-detected diabetes? Diabetes Med 25 2008 1433 1439